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Racial Disparities in the Utilization and Outcomes of Structural Heart
Disease Interventions in the United States
Mohamad Alkhouli, MD; Fahad Alqahtani, MD; David R. Holmes, MD; Chalak Berzingi, MD
Background-—Data on race- and ethnicity-based disparities in the utilization and outcomes of structural heart disease
interventions in the United States are scarce.
Methods and Results-—We used the National Inpatient Sample (2011-2016) to examine racial and ethnic differences in the
utilization, in-hospital outcomes, and cost of structural heart disease interventions among patients ≥65 years of age. A total of
106 119 weighted hospitalizations for transcatheter aortic valve replacement, transcatheter mitral valve repair, and left atrial
appendage occlusion were included. The utilization rates (defined as the number of procedures performed per 100 000 US people
>65 years of age) were higher in whites compared with blacks and Hispanics for transcatheter aortic valve replacement (43.1
versus 18.0 versus 21.1), transcatheter mitral valve repair (5.0 versus 3.2 versus 3.2), and left atrial appendage occlusion (6.6
versus 2.1 versus 3.5), respectively (P<0.001). Black and Hispanic patients had distinctive socioeconomic and clinical risk profiles
compared with white patients. There were no significant differences in the adjusted in-hospital mortality or key complications
between patients of white race, black race, and Hispanic ethnicity following transcatheter aortic valve replacement, transcatheter
mitral valve repair, or left atrial appendage occlusion. No difference in cost was observed between white and black patients
following any of the 3 procedures. However, Hispanic patients incurred modestly higher cost with transcatheter mitral valve repair
and left atrial appendage occlusion compared with white patients.
Conclusions-—Racial and ethnic disparities exist in the utilization of structural heart disease interventions in the United States.
Nonetheless, adjusted in-hospital outcomes were comparable among white, black, and Hispanic patients. Further studies are
needed to understand the reasons for these utilization disparities. ( J Am Heart Assoc. 2019;8:e012125. DOI: 10.1161/JAHA.
119.012125.)
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R acial and ethnic disparities in the access, provision ofcare, and outcomes of cardiovascular interventions are
well documented.1-4 However, whether such disparities exist
in the rapidly growing field of structural heart disease (SHD)
interventions is unknown. The current literature is limited to a
few studies suggesting less utilization but acceptable short-
term outcomes of transcatheter aortic valve replacement
(TAVR) in patients of black race.5,6 However, large-scale data
on the impact of race/ethnicity on the utilization and
outcomes of TAVR and other SHD interventions are lacking.
We sought to investigate race- and ethnicity-based disparities
in the utilization and outcomes of the 3 most common SHD
interventions: TAVR, transcatheter mitral valve repair (TMVr),
and percutaneous left atrial appendage occlusion (LAAO)
using a national representative database.
Methods
Study Data
The Nationwide Inpatient Sample (NIS) was queried to derive
patient-relevant information between November 2, 2011 and
December 31, 2016. The NIS is the largest publicly available
all-payer claims-based database. We selected November 2,
2011 as the starting time for our study because it was the
date when TAVR was approved by the Food and Drug
Administration. The NIS contains data on patient discharges
from 1000 hospitals in 45 states, with safeguards to protect
the privacy of individual patients, physicians, and hospitals.
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These data are stratified to represent 20% of US inpatient
hospitalizations across different hospital and geographic
regions (random sample). National estimates of the entire
US hospitalized population are calculated using the Agency
for Healthcare Research and Quality sampling and weighting
method. The Institutional Review Board exempted the study
from board approval and waived the requirement for informed
consent because the NIS is a publically available deidentified
database.
Study Population
Patients who underwent TAVR, TMVr, and LAAO during the
specific study period were identified using International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) and Tenth Revision (ICD-10-CM) codes (TAVR,
35.05, 35.06, 02RF3JZ, 02RF3KZ, 02RF38Z, 02RF37Z,
02RF3JZ, 02RF37H, 02RF38H, 02RF3JH, 02RF3KH; TMVr,
35.97, 02UG3JZ; and LAAO, 37.90, 02L73DK). We excluded
patients with missing race information, those with procedures
performed before Food and Drug Administration approval
(October 25, 2013 for TMVr and March 13, 2015 for LAAO;
Figure 1). We also confined our analysis to patients of white,
black, and Hispanic origin. The numbers of patients of Asian,
Native American, Pacific Islander, or “other” races were too
small to allow meaningful analyses.
Study End Points
The primary end point was procedure utilization rate per race/
ethnicity defined as the number of procedures performed per
100 000 US people >65 years of age. We selected this cutoff
to minimize the potential confounding issue of lack of
insurance coverage, given that most patients >65 years of
age are eligible for the Centers of Medicare & Medicaid
Services. The estimated numbers of white, black, and Hispanic
population >65 years of age were obtained from the US
Census website (www.census.gov). Secondary end points
were risk-adjusted rates of in-hospital mortality and major
morbidities for each procedure stratified by race/ethnicity.
Statistical Analyses
Weighted data were used for all statistical analyses. Descriptive
statistics are presented as frequencies with percentages for
categorical variables. Mean, standard deviation, median, 25th
percentile, and 75th percentile are reported for continuous
measures. To examine the association of race/ethnicity with
intervention of choice and outcomes, multivariate logistic
regression models were constructed using generalized esti-
mating equations to account for the clustering of outcomes
within hospitals. The following variables were included in the
logistic regression risk adjustment model: age, sex, comor-
bidities (hypertension, diabetes mellitus, hyperlipidemia, coro-
nary disease, congestive heart failure, carotid artery disease,
vascular disease, prior sternotomy, chronic lung disease, renal
insufficiency, liver cirrhosis, anemia, conduction disorder, atrial
fibrillation, prior pacemaker or defibrillator, history of stroke,
smoking), hospital characteristics (hospital size, urban versus
rural location, teaching status), and socioeconomic factors
(payer status, median household income). Odds ratios and 95%
CIs were used to report the results of logistic regression.
Further adjustments were made using the Bonferroni correc-
tion method to account for multiple comparisons of racial/
ethnic groups. All P values were 2-sided with a significance
threshold of <0.05. All statistical analyses were performed with
SPSS version 24 (IBM Corporation, Armonk, NY).
Cost Analysis
The NIS contains data on total charges (the amount that
hospitals billed for services) for each hospital discharge in
Figure 1. Study flowchart. FDA indicates Food and Drug
Administration; LAAO, left atrial appendage occlusion; N, number;
NIS, National Inpatient Sample; SHD, structural heart disease;
TAVR, transcatheter aortic valve replacement; TMVr,
transcatheter mitral valve repair. *Weighted.
Clinical Perspective
What Is New?
• Racial and ethnic disparities exist in the utilization of
contemporary structural heart disease interventions in the
United States.
• The magnitude of this disparity varies among different
procedures.
What Are the Clinical Implications?
• There is an unmet need to understand the etiology of racial
and ethnic disparity in structural heart disease interventions
and to identify effective strategies for its mitigation.
DOI: 10.1161/JAHA.119.012125 Journal of the American Heart Association 2
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the databases. However, the Agency for Healthcare
Research and Quality provides supplementary cost-to-
charge ratio files that allow accurate conversion of the
hospital total charge data to cost estimates by multiplying
total charges with the appropriate cost-to-charge ratio. The
cost information used to calculate the cost-to-charge ratio
for each hospital was obtained from the hospital accounting
reports collected by the Centers for Medicare & Medicaid
Services.
Results
Utilization Rate of SHD Interventions Per Race/
Ethnicity
A total of 106 119 weighted hospitalizations for SHD interven-
tions were included in our analysis. In the overall cohort, white
patients constituted 91.7%, 88.5%, and 92.3% of all patients
who underwent TAVR, TMVr, and LAAO, respectively. The
utilization rate (number of procedures/100 000 people
>65 years of age) was significantly higher in white patients
compared with black and Hispanic patients for all 3 procedures:
TAVR (43.1 versus 18.0 versus 21.1), TMVr (5.0 versus 3.2
versus 3.2), and LAAO (6.6 versus 2.1 versus 3.5), respectively
(P<0.001; Figure 2). Regional variations were, however,
observed in the percentage of black and Hispanic patients
among all patients undergoing SHD interventions (Table 1).
Baseline Risk Profile Among Racial Groups
There were notable differences in demographic, socioeco-
nomic, and clinical characteristics across the racial/ethnic
groups. Across all 3 SHD interventions, black and Hispanic
patients were younger, included more women, and were more
likely to be treated at urban, teaching, and large hospitals
than patients of white race (Table 2). They also had signif-
icantly higher proportions of patients in the lowest quartile of
household income. Clinical risk profile also differed among the
3 groups. Hypertension and diabetes mellitus were more
prevalent among black and Hispanic patients. Black patients
also had significantly higher prevalence of renal insufficiency
and anemia but less prior sternotomy compared with white
patients. Differences in the prevalence in clinical risk factors
among the 3 racial/ethnic groups are shown in Table 2.
Figure 2. Racial and ethnic differences in the utilization of common structural heart interventions in the United States. A, Racial/ethnic
differences in the utilization of TAVR. B, Racial/ethnic differences in the utilization of TMVr. C, Racial/ethnic differences in the utilization of
LAAO. LAAO indicates left atrial appendage occlusion; TAVR, transcatheter aortic valve replacement; TMVr, transcatheter mitral valve repair.
Table 1. Regional Variations in Distribution of White, Black,
and Hispanic Patients Among all Patients Undergoing Common
Structural Heart Disease Interventions in the United States
Race/Ethnicity
Region
Northeast Midwest South West
TAVR
White 94.3% 95.1% 90.4% 89.0%
Black 3.3% 3.8% 5.2% 2.3%
Hispanic 2.4% 1.0% 4.4% 8.6%
TMVr
White 91.6% 91.9% 87.1% 87.7%
Black 5.9% 4.8% 5.9% 3.1%
Hispanic 2.5% 3.2% 7.0% 9.2%
LAAO
White 87.0% 89.4% 87.9% 87.5%
Black 4.3% 4.3% 4.4% 2.1%
Hispanic 2.2% 2.1% 3.3% 10.4%
LAAO indicates left atrial appendage occlusion; TAVR, transcatheter aortic valve
replacement; TMVr, transcatheter mitral valve repair.
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Outcomes and Cost of SHD Interventions
Stratified by Race/Ethnicity
Despite the underutilization of SHD interventions in racial
and ethnic minorities, no significant differences in hospital
outcomes were observed with a few exceptions. With TAVR
there were no statistically significant differences in in-
hospital death, key post-TAVR complications, or rate of
nonhome discharge among the 3 groups (Table 3). Similarly,
in-hospital outcomes following TMVr and LAAO were similar
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94.0% 90.9% 91.4% <0.001 93.9% 91.6% 89.0% <0.001 95.3% 100% 96.2% 0.001
Urban location 85.0% 88.3% 87.2% <0.001 91.4 90.9% 94.5% <0.001 93.6% 972% 100% <0.001
Teaching hospital 88.9% 93.7% 92.7% <0.001 91.4% 100% 97.6% <0.001 85.4% 100% 86.7% 0.032
Large hospital 76.0% 80.6% 78.3% <0.001 75.1% 73.5% 85.4% <0.001 64.6% 87.5% 80.0% <0.001
0 to 25th percentile
income*
20.1% 50.6% 33.4% <0.001 21.8% 54.4% 28.2% <0.001 17.0% 38.9% 36.0% <0.001
Medical comorbidities, %
Diabetes mellitus 35.6% 45.8% 48.3% <0.001 23.2% 32.5% 45.2% <0.001 28.3% 41.7% 48.1% <0.001
Hypertension 83.9% 87.6% 86.8% <0.001 79.0% 86.7% 82.2% <0.001 81.5% 94.4% 90.4% <0.001
Hyperlipidemia 42.2% 38.7% 40.5% <0.001 28.8% 25.3% 34.2% 0.021 15.4% 19.4% 21.2% 0.017
Congestive heart
failure
36.2% 39.9% 36.9% <0.001 46.8% 61.4% 43.8% <0.001 24.5% 36.1% 36.5% <0.001
Carotid artery
disease
7.6% 5.3% 5.8% <0.001 2.7% 3.6% 1.4% 0.148 1.8% 1.0% 3.8% 0.01
Coronary artery
disease
58.6% 58.7% 59.6% 0.423 53.2% 51.8% 47.9% 0.130 46.4% 30.6% 40.4% <0.001
Vascular disease 25.9% 25.8% 25.8% 0.974 14.5% 14.5% 12.3% 0.524 9.3% 16.7% 9.6% 0.005
Renal insufficiency 35.4% 48.5% 39.3% <0.001 37.5% 57.8% 37.0% <0.001 19.0% 50.0% 17.3% <0.001
Obstructive lung
disease
30.7% 30.5% 29.1% 0.084 28.4% 34.9% 12.3% <0.001 15.7% 25.0% 11.5% 0.001
Liver cirrhosis 1.1% 0.9% 1.5% <0.001 0.7% 0.6% 2.7% <0.001 0.8% 2.8% 1.9% 0.003
Anemia 24.3% 36.0% 35.4% <0.001 23.8% 33.7% 26.0% <0.001 13.8% 27.8% 23.1% <0.001
AFib/flutter 45.6% 30.0% 32.7% <0.001 64.1% 50.6% 60.3% <0.001 99.6% 97.2% 100.0% <0.001
Conduction disorders 17.2% 14.5% 18.5% <0.001 4.7% 2.4% 4.1% 0.095 3.4% 1.2% 1.9% 0.019
Prior ICD/pacemaker 14.5% 9.8% 14.3% <0.001 23.7% 28.9% 23.3% 0.053 26.5% 27.8% 21.2% 0.144
Prior sternotomy 23.4% 12.5% 22.7% <0.001 29.8% 16.9% 39.7% <0.001 20.7% 2.8% 13.5% <0.001
Prior stroke 12.2% 11.9% 9.7% <0.001 13.8% 10.8% 15.1% 0.173 23.9% 30.6% 25.0% 0.113




4.1%2.8 6.24.1 4.63 <0.001 4.22.7 7.54 4.22.7 <0.001 5.12 9.43 5.22.4 <0.001
AFib indicates atrial fibrillation; ICD, internal cardioverter defibrillator; LAAO, left atrial appendage occlusion; n, number; SHD, structural heart disease; TAVR, transcatheter aortic valve
replacement; TMVr, transcatheter mitral valve repair.
*Based on the average household income for the residence zip code.
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across all racial/ethnic groups (Table 4). Although there
were statistically significant differences in the cost of SHD
procedures among the 3 groups, the magnitudes of these
differences were small (Table 5).
Discussion
There were 3 salient findings of our study. (1) Common SHD
interventions are performed less frequently in black andHispanic
patients comparedwithwhite patients. (2) Significantdifferences
exist in demographic, socioeconomic, and clinical characteristics
among white, black, and Hispanic patients who undergo SHD
interventions in contemporary US practice. (3) In-hospital
morbidity, mortality, and the cost of common SHD interventions
were comparable across the 3 racial/ethnic groups.
A main highlight of our findings is that black and Hispanic
patients each constituted only 4% of the total population of
patients who underwent a SHD intervention between 2011
and 2016 in the United States. This is in contrast with their
much higher representation in the overall elderly US popula-
tion aged >65 years (11%, and 7%, respectively). Although
striking, this finding is in agreement with several previous
similar observations. For example, among all patients who
underwent surgical aortic valve replacement in the United
States between 1999 and 2011, only 3.2% were black.7
Similar observations were made with regard to TAVR. In the
Society of Thoracic Surgery/American College of Cardiology
Transcatheter Valve Therapy (ACC/STS TVT) registry, black
and Hispanic patients each constituted 3.4% of the overall
TAVR population between 2012 and 2015.8,9 Also, black and
Hispanic patients constitute only 5.8% and 4.7% of patients
who underwent TMVr in the ACC/STS TVT registry between
November 2013 and September 2015, respectively.10
Although the racial differences in the utilization rate appear
to be less striking with TMVr than with TAVR, caution should
be used in interpreting these data due to the small number of
patients of racial and ethnic minorities overall who underwent
TMVr in the early commercial experience in the United States.
The etiology of these large differences in the utilization of
common SHD interventions is likely multifactorial, including
race- and ethnic-specific differences in the prevalence of
specific cardiac pathologies (eg, aortic stenosis), lack of access
to advanced SHD interventions, differences in cultural values
and acceptance of invasive treatment, or system-related biases
in the provision of care to racial and ethnic minorities. For
example, Patel et al found that the prevalence of severe aortic
stenosis in black patients is much lower than its prevalence in
white patients (0.29% versus 0.91%, adjusted odds ratio 0.41,
95% CI 0.33-0.50, P<0.001), although no difference existed in
the prevalence of severe mitral regurgitation between the 2
Table 3. In-Hospital Outcomes Following Transcatheter Aortic Valve Replacement Stratified by Race/Ethnicity
In-Hospital Outcomes Race/Ethnicity Unadjusted Rate Adjusted Rate OR 95% CI P Value
Bonferroni Adjusted
P Value
Death White 2.8% Reference
Black 2.1% 2.20% 0.79 0.63 to 0.99 0.04 0.11
Hispanic 3.3% 2.38% 1.12 0.91 to 1.38 0.28 0.84
Stroke White 2.3% Reference
Black 2.6% 2.31% 1.01 0.79 to 1.28 0.21 0.99
Hispanic 2.3% 2.19% 0.95 0.67 to 1.09 0.96 0.62
Pacemaker White 12.6% Reference
Black 13.0% 13.40% 1.06 0.96 to 1.17 0.25 0.74
Hispanic 15.4% 16.21% 1.29 1.17 to 1.41 <0.001 <0.001
New dialysis White 1.1% Reference
Black 1.6% 1.20% 1.11 0.87 to 1.42 0.40 0.90
Hispanic 1.8% 1.24% 1.13 0.89 to 1.44 0.32 0.95
Vascular complications White 7.0% Reference
Black 6.6% 6.40% 0.92 0.81 to 1.05 0.22 0.67
Hispanic 9.5% 10.21% 1.46 1.30 to 1.63 <0.001 <0.001
Nonhome discharge White 25.3% Reference
Black 25.4% 24.50% 1.00 0.93 to 1.09 0.95 0.99
Hispanic 21.8% 21.50% 0.85 0.78 to 0.92 <0.001 <0.001
OR indicates odds ratio.
DOI: 10.1161/JAHA.119.012125 Journal of the American Heart Association 5
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groups (1.35% in whites versus 1.45% in blacks, respectively).11
Other studies have also reported significantly lower prevalence
of aortic stenosis and atrial fibrillation among black and
Hispanic patients compared with white patients.1,11-13 How-
ever, differences in access to care and acceptance of invasive
interventions among various racial and ethnic groups are well
documented.13,14 In addition, over half of the patients of black
race were classified in the lowest household income quartile
compared with 20% of white patients. Whether this striking
difference in the socioeconomic status among patients of
various racial groups is associatedwith less access to advanced
care among these groups remains to be studied. Assessing the
role of these and other factors on the observed disparity
requires a dedicated prospective registry that collects data on
epidemiological, clinical, and demographic characteristics
among different racial groups.
Table 4. In-Hospital Outcomes Following Transcatheter Mitral Valve Repair and Left Atrial Appendage Occlusion Stratified by
Race/Ethnicity
In-Hospital Outcomes Race/Ethnicity Unadjusted Rate Adjusted Rate OR 95% CI P Value
Bonferroni Adjusted
P Value
Transcatheter mitral valve repair
Death White 2.2% Reference
Black 1.6% 1.52% 0.69 0.41 to 1.17 0.17 0.38
Hispanic 1.9% 1.80% 0.82 0.46 to 1.45 0.49 0.99
Stroke White 0.8% Reference
Black 1.6% 1.16% 1.45 0.84 to 2.48 0.18 0.77
Hispanic 0.9% 0.97% 1.22 0.72 to 2.05 0.47 0.99
New dialysis White 1.0% Reference
Black 2.3% 1.47% 1.47 0.89 to 2.40 0.13 0.54
Hispanic 1.9% 1.30% 1.29 0.78 to 2.14 0.32 0.99
Vascular complications White 4.7% Reference
Black 2.4% 3.14% 0.67 0.39 to 1.16 0.15 0.45
Hispanic 2.7% 2.90% 0.62 0.34 to 1.10 0.10 0.30
Nonhome discharge White 14.7% Reference
Black 11.9% 13.30% 0.90 0.70 to 1.16 0.43 0.99
Hispanic 13.5% 16.98% 1.15 0.90 to 1.47 0.25 0.80
Left atrial appendage occlusion
Pericardial tamponade White 0.8% Reference
Black 2.8% 1.40% 1.83 0.67 to 4.96 0.24 0.71
Hispanic 0.5% 0.53% 0.66 0.42 to 1.05 0.08 0.23
Nonhome discharge White 4.4% Reference
Black 8.3% 5.14% 1.17 0.72 to 1.90 0.53 0.99
Hispanic 7.7% 6.36% 1.45 0.86 to 2.43 0.16 0.49
OR indicates odds ratio.




















TAVR $49 424 $38 452 $63 407 $49 328 $38 492 $65 900 0.88 $51 295 $40 152 $67 846 0.06
TMVr $42 764 $32 295 $57 710 $41 410 $31 447 $52 995 0.36 $40 875 $33 198 $54 556 <0.001
LAAO $24 304 $18 206 $31 050 $25 596 $16 502 $30 400 0.06 $26 467 $21 002 $34 310 <0.001
$ indicates US dollar; LAAO, left atrial appendage occlusion; TAVR, transcatheter aortic valve replacement; TMVr, transcatheter mitral valve repair.
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Our study also suggests no differential impact of race/
ethnicity on the morbidity, mortality, and cost of common SHD
interventions with the exception of a modestly higher cost of
TMVr and LAAO in Hispanic patients. These data are reassuring
and are in line with prior studies suggesting comparable
adjusted outcomes of surgical and transcatheter valvular
interventions among patients of various races.1,5,6,15,16
Nonetheless, these findings need to be confirmed in further
studies given the youth of the SHD interventional field and the
small number of patients of racial and ethnic minorities who
have received those interventions to date.
Limitations
First, the NIS is an administrative database that collects data for
billing purposes. Hence, it is subject to under-, over-, or
erroneous coding. However, accurate coding for high-cost
procedures and hard clinical end points (eg, death) are highly
incentivized, and hence, this limitation is unlikely to impact the
main end points of our study. Second, excluding patients with
missing race data or patients with races or ethnicities other
than white, black, and Hispanic might affect the outcomes of
this study. Nonetheless, racewas recorded in 93.7% of patients.
Third, race is self-reported and not verified, which can lead to
ascertainment bias in certain racial minorities. Fourth, although
rigorous risk adjustment was performed for secondary end
points, data on laboratory values, imaging findings, and
procedural characteristics are not available in the NIS. Hence,
differences in these parameters among the 3 groups in our
study could not be adjusted for. Fifth, this study spans the early
US experience with SHD interventions (2011-2016). Whether
some of our results could be explained by the limited access to
such interventions in their early commercial dissemination
remains uncertain. However, this is unlikely to be amajor factor,
as patients of racial or ethnic minorities are more likely to
receive care at large, urban, and teaching hospitals, which are
more likely to offer those procedures. Finally, the procedural
rate stratified by race is calculated by dividing the number of
procedures in each racial group by the number of US adults
>65 years of age in the same group. Although uncommon, in
some procedures (eg, TAVR, TMVr), a small number of patients
could have had a repeat procedure during the study period, and
this might have affected the calculation. However, the
percentage of those patients in contemporary registries is
<0.5%, and this is unlikely to impact our results.10,17
Conclusions
Significant racial and ethnic disparities exist in the utilization of
common SHD interventions and in the characteristics of patients
undergoing these procedures in the United States. However,
after risk adjustments, no differences were noted in short-term
outcomes among white, black, and Hispanic patients. Further
studies are needed to understand the reasons for these
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